secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107780
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q3 LOQTORZI rev up 92% YoY to $11.2M; net loss narrows to $44.5M; CHS-114 enters colorectal cancer
--------------------------------------------------------------------------------

- Net revenue $11.6M (up 90% YoY); LOQTORZI net revenue $11.2M (+12% QoQ, +92% YoY).
- GAAP net loss from continuing ops $44.5M (-$0.38/sh) vs $47.6M (-$0.41/sh) prior year.
- Non-GAAP net loss $38.9M (-$0.33/sh) vs $40.0M (-$0.35/sh); cash at $191.7M.
- CHS-114 Phase 1b/2a enrolling in 4L+ colorectal cancer; initial data expected 2H 2026.
- Casdozokitug Phase 2 in 1L HCC enrollment ongoing; first data readout mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/0001104659-25-107780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/chrs-20251106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer